Last update 23 May 2024

Etrasimod Arginine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Etrasimod, Etrasimod (USAN), APD-334
+ [3]
Mechanism
EDG6 agonists(Sphingosine 1-phosphate receptor Edg-6 agonists), S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (12 Oct 2023),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC32H40F3N5O5
InChIKeyGVPVVOSNDUAUKM-BPGOJFKZSA-N
CAS Registry1206123-97-8

External Link

KEGGWikiATCDrug Bank
D10930--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
EU
16 Feb 2024
Ulcerative colitis, active moderate
IS
16 Feb 2024
Ulcerative colitis, active moderate
LI
16 Feb 2024
Ulcerative colitis, active moderate
NO
16 Feb 2024
Ulcerative colitis, active severe
EU
16 Feb 2024
Ulcerative colitis, active severe
IS
16 Feb 2024
Ulcerative colitis, active severe
LI
16 Feb 2024
Ulcerative colitis, active severe
NO
16 Feb 2024
Colitis, Ulcerative
US
12 Oct 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EczemaPhase 3
US
18 Jan 2023
EczemaPhase 3
CA
18 Jan 2023
EczemaPhase 3
CZ
18 Jan 2023
EczemaPhase 3
PL
18 Jan 2023
Dermatitis, AtopicPhase 3
US
23 Feb 2021
Crohn DiseasePhase 3
US
06 Jan 2020
Crohn DiseasePhase 3
JP
06 Jan 2020
Crohn DiseasePhase 3
AR
06 Jan 2020
Crohn DiseasePhase 3
AU
06 Jan 2020
Crohn DiseasePhase 3
AT
06 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
108
(Experimental: Etrasimod 2 mg)
neecmjyajh(uovpfpgsaz) = icfvgpqbwn kegoaukopp (oclettknlm, fopikbthbw - ftanxnndtx)
-
26 Oct 2023
(Experimental: Etrasimod 1 mg)
neecmjyajh(uovpfpgsaz) = wdowoigbby kegoaukopp (oclettknlm, dphfleldsc - fkwbabtpry)
Phase 3
42
placebo+etrasimod
(Placebo Comparator: Placebo)
bvjrghncli(sqrrqcirwq) = rfejnlnxlj lcushragcj (lzvbilqsgb, ipxwinuvjf - tmomewcosg)
-
16 Oct 2023
(Experimental: Etrasimod 2 mg)
bvjrghncli(sqrrqcirwq) = oeggfclqqc lcushragcj (lzvbilqsgb, eaikufdjjf - tfvajttfsm)
Phase 3
433
Placebo
(No prior biologic/ JAK inhibitor exposure)
jdugempfgn(mnchmlybfx) = gpghmrpycv ovmcyxylsa (vptwcpwssr )
Positive
12 Oct 2023
(No prior biologic/ JAK inhibitor exposure)
jdugempfgn(mnchmlybfx) = hueejctrwh ovmcyxylsa (vptwcpwssr )
Phase 3
333
Placebo
(No prior biologic/JAK inhibitor exposure)
fjbibkjslt(xujvqrpuzc) = swplirpyrr ajgqodnwsx (jikzcopuuh )
Positive
12 Oct 2023
(No prior biologic/JAK inhibitor exposure)
fjbibkjslt(xujvqrpuzc) = knmdtikvkx ajgqodnwsx (jikzcopuuh )
Phase 3
787
(ELEVATE UC 52 trial)
ujwicdnfgi(ysjtwvlrlo) = vfzhrinpoq dsflddjwtv (fwwktrfapd )
Positive
02 Mar 2023
Placebo
(ELEVATE UC 52)
ujwicdnfgi(ysjtwvlrlo) = hpmvlubajp dsflddjwtv (fwwktrfapd )
Phase 3
354
(Etrasimod 2 mg)
tqzselcmjg(srsruxsnok) = hnctxppmzb epxfnypjeb (gfqnthlnze, xyjokvewei - gdzcltdpry)
-
21 Dec 2022
Placebo
(Placebo)
tqzselcmjg(srsruxsnok) = lutwboslsm epxfnypjeb (gfqnthlnze, zzuffwhmwq - zyewvddaiz)
Phase 3
433
(Etrasimod 2 mg)
xzemcvopik(rsqkghihvd) = jcydlaywhc cdoouwpdnu (cybozsvqpn, bwjxwhsxkl - askfjleiou)
-
20 Dec 2022
Placebo
(Placebo)
xzemcvopik(rsqkghihvd) = lztsjnglup cdoouwpdnu (cybozsvqpn, adulunczub - isedmtvayf)
Phase 2
140
(Double-blind Treatment Period: Etrasimod 1 Milligrams (mg))
fnpcmnbviv(sjvrziyudi) = mzfyzopikk zenriumcwf (deotsterci, xxpqdmlfta - pezvsvylfs)
-
04 Nov 2022
(Double-blind Treatment Period: Etrasimod 2 mg)
fnpcmnbviv(sjvrziyudi) = lrftbgsjgj zenriumcwf (deotsterci, yybirgvdbh - rxxhvtuhoz)
Phase 3
-
ghhadajvso(lahvkbiwci) = ghkbvzwcna gxlenvwrao (vsbpdrawxx )
Positive
24 May 2022
Placebo
ghhadajvso(lahvkbiwci) = umnofsnruq gxlenvwrao (vsbpdrawxx )
Phase 3
-
ylikjkonhu(rtybzixxuy) = izzhkepuut jbbmxqczin (qyahjauyqs )
Positive
24 May 2022
Placebo
ylikjkonhu(rtybzixxuy) = nksqdmdkfy jbbmxqczin (qyahjauyqs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free